Metadichol®, A Novel Nano Lipid Formulation that Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses in Vitro

44 Pages Posted: 7 Jul 2020

Date Written: June 30, 2020

Abstract

New pathogenic virus outbreaks, occurring with increasing regularity, are leading us to explore novel approaches, which will reduce the reliance on time-consuming vaccine modes to halt the outbreaks. The requirement is to find a universal approach to disarm any new and as yet unknown viruses as they appear. A promising approach could be targeting lipid membranes, which are common to all viruses and bacteria.

The ongoing pandemic of severe acute respiratory syndrome-coronavirus 2 (SARS-COV-2) has reaffirmed the importance of interactions between components of the host cell plasma membrane and the virus envelope as a critical mechanism of infection. Metadichol®, a nano lipid emulsion, has been examined and shown to be a strong candidate to help stop the proliferation of SARS-COV-2.

Naturally derived substances, such as long-chain saturated lipid alcohols, reduce the infectivity of various types of viruses, including coronaviruses such as SARS-COV-2, by modifying lipid-dependent attachment to human host cells. SARS-COV-2 uses the receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.

Metadichol®, a nano lipid formulation of long-chain alcohols, has been shown to inhibit TMPRSS2 (EC50 96 ng/ml). Compared to the inhibitor camostat mesylate (EC50 26000 ng/ml), it is 270 times more potent. Additionally, Metadichol® is also a weak inhibitor of ACE2 at 31 µg/ml. Further a live virus assay in Caco2 cells, Metadichol® inhibited SARS-CoV-2 replication with an EC90 of 0.16 µg/ml.

Note: Conflict of Interest: None.

Funding: We are a privately held company and the funding is part of our R and D budget.

Keywords: Coronavirus, SARS-COV-2, COVID-19, ACE2, TMPRSS2, VDR, Metadichol

Suggested Citation

raghavan, Palayakotai, Metadichol®, A Novel Nano Lipid Formulation that Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses in Vitro (June 30, 2020). Available at SSRN: https://ssrn.com/abstract=3638748 or http://dx.doi.org/10.2139/ssrn.3638748

Palayakotai Raghavan (Contact Author)

Nanorx Inc ( email )

po Box 131
chappaqua, NY 10514
United States
9146710224 (Phone)

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
65
Abstract Views
1,189
rank
390,736
PlumX Metrics